NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. On July 7, 2025, Molina issued preliminary financial results for the second quarter of 2025, reporting adjusted earnings of approximately $5.50 per share. In the same announcement, the Company lowered its full-year 2025 adjusted earnings gu ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Duolingo, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - JMP Securities has lowered its price target on Duolingo stock from $475 to $450 due to concerns about slowing user engagement, with daily active user growth decelerating to approximately 39% year-over-year in Q2 from about 51% in Q1 [2] - Following the news of the lowered price target, Duolingo's stock price fell by $23.60 per share, or 6.48%, closing at $340.49 per share on July 28, 2025 [3]

Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by these conversions, masking a slowdown in acquiring new merchants [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service, leading to a significant slowdown in Clover's growth [2]. - The lawsuit asserts that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

LOS ANGELES, July 31, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sable Offshore Corp. ("Sable" or "the Company") (NYSE: SOC) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 21, 2025 secondary public offering (the "SPO") and/or between May 19, 2025 and June 3, 2025, both dates inclusive (the "Class Period"), are enco ...

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response to their biologics license application for RP1 [1][2][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. - The company announced positive results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application to the FDA based on these results [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Replimune securities [2]. - The complaint alleges that the IGNYTE Phase 1/2 trial design was inadequate to produce reliable results, despite the company promoting its outcomes [4]. Group 3: Stock Performance - Following the FDA's Complete Response Letter on July 22, 2025, which indicated that the IGNYTE trial was not considered adequate for demonstrating effectiveness, Replimune's stock price fell by more than 75% [5].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration of its business with 3M's Food Safety Division and the financial implications of this merger [1][3][4]. Company Overview - Neogen Corporation specializes in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. Class Action Details - The class action lawsuit is titled "Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation" and allows investors who purchased Neogen common stock between January 5, 2023, and June 3, 2025, to seek appointment as lead plaintiff by September 16, 2025 [1][7]. - The lawsuit alleges that Neogen's executives made false statements about the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3][4]. Financial Performance - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in fiscal year 2025 revenue and EBITDA guidance [4]. - In the third quarter of 2025, Neogen reported a loss of $11 million, a significant increase from a $2 million loss the previous year, with revenue declining by 3.4% to $221 million due to integration issues [5]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from 22%, attributing this to elevated inventory write-offs, which led to a further decline in stock price by over 17% [6].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for alleged violations of federal securities laws, focusing on misleading statements and operational issues related to its Payeezy and Clover platforms [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks damages for investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, inclusive [2]. - Allegations include that Fiserv forced Payeezy merchants to transition to Clover due to cost-related issues, leading to inflated revenue growth figures for Clover [3]. - It is claimed that many former Payeezy merchants abandoned Clover for competitors due to high pricing and poor customer service, resulting in a deceleration of Clover's growth [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Fiserv have until September 22, 2025, to request appointment as lead plaintiff in the class action [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - Harrow reported Q1 2025 revenue of $47.8 million, which was below the consensus estimate of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving American Outdoor Brands, Inc. and its officers or directors [1] Financial Performance - On June 26, 2025, American Outdoor reported its financial results for Q4 and the full fiscal year 2025, revealing that retailers accelerated orders, pulling forward an estimated $8 million to $10 million in sales from the upcoming fiscal year [3] - The company announced the suspension of its fiscal 2026 guidance due to uncertainties surrounding tariffs [3] Stock Market Reaction - Following the financial results announcement, American Outdoor's stock price dropped by $1.57 per share, or 13.13%, closing at $10.39 per share on June 27, 2025 [4]